Should Epstein-Barr virus serology be checked before initiating azathioprine or biologic therapy in patients with inflammatory bowel disease?

EBV Screening Before Azathioprine or Biologic Therapy in IBD

EBV serology should be checked before initiating azathioprine in patients with IBD, particularly in pediatric patients and young adults, though routine screening in all adults remains controversial. For biologics alone (without thiopurines), EBV screening is less critical but may be considered as part of comprehensive viral screening.

Evidence-Based Rationale

The 2019 British Society of Gastroenterology guidelines explicitly address this question 1. The guidelines state that routine EBV testing prior to thiopurine therapy remains controversial in adults, but there is more justification for screening in pediatric patients who are particularly at risk from primary EBV infection, in order to avoid thiopurine use in those who are seronegative 1.

Risk Stratification by Age and EBV Status

The evidence demonstrates clear age-related differences in risk:

Pediatric and Young Adult Patients:

• Primary EBV infection in EBV-seronegative patients on thiopurines carries significant risk of severe complications including haemophagocytic syndrome and lymphoproliferative disorders 1
• Research shows 40-50% of pediatric IBD patients are EBV-seronegative at diagnosis 2, 3, 4
• The absolute risk of lymphoproliferative disorders in young EBV-naïve patients on thiopurines is approximately 3/1000 patient-years 5
• Screening is strongly justified in this population to inform treatment decisions

Adult Patients:

• Approximately 97% of adults are EBV-seropositive 6
• A Spanish study of 1,483 adult IBD patients found that lymphoma risk on azathioprine is not restricted to young males—complications occurred across age groups, including a 66-year-old man 1, 6
• The remaining 3% of seronegative adults maintain seroconversion risk of approximately 30% over 4 years 6

Specific Complications Associated with EBV and Thiopurines

The FDA label for azathioprine warns about increased malignancy risk, particularly hepatosplenic T-cell lymphoma in IBD patients, with the majority occurring in adolescent and young adult males 7. However, the BSG guidelines clarify this risk extends beyond this demographic 1.

Documented complications include:

• Haemophagocytic lymphohistiocytosis (particularly during primary infection) 1, 8
• Post-mononucleosis type lymphomas (after primary infection) 1
• Post-transplant type lymphoma (during latent infection) 1
• EBV-positive mucocutaneous ulcer and diffuse large B-cell lymphoma 9

EBV Screening and Biologic Therapy

For biologic monotherapy (anti-TNF, vedolizumab, ustekinumab, tofacitinib):

• The 2019 BSG guidelines recommend viral screening (including EBV) as part of a comprehensive panel before starting biologics or immunosuppressive drugs 1
• However, the risk profile differs significantly from thiopurines
• Meta-analysis shows biologics carry a two-fold increased risk of opportunistic infections including EBV, but this is lower than with thiopurines 1
• EBV screening before biologics is reasonable as part of comprehensive viral screening but is less critical for treatment decisions compared to thiopurines

Practical Implementation Algorithm

For Azathioprine/Thiopurine Initiation:

1. Check EBV IgG serology in all patients before starting thiopurines (particularly those <35 years)

2. If EBV IgG-positive (seropositive):

   • Proceed with azathioprine if clinically indicated
   • Standard monitoring applies

3. If EBV IgG-negative (seronegative):

   • Pediatric patients (<18 years): Strongly consider alternative immunosuppression (methotrexate, biologics)
   • Young adults (18-35 years): Discuss risks; consider alternatives or enhanced monitoring
   • Adults (>35 years): Individual risk-benefit discussion; may proceed with informed consent and monitoring
   • If thiopurines used in seronegative patients: monitor for symptoms of primary EBV infection (fever, pharyngitis, lymphadenopathy, hepatitis)

For Biologic Therapy:

1. Perform comprehensive viral screening panel including EBV IgG as part of pre-treatment workup 1
2. This is part of standard infectious disease screening (hepatitis B, C, HIV, VZV, EBV) rather than a specific contraindication to therapy
3. EBV status does not typically alter biologic treatment decisions

Common Pitfalls to Avoid

• Don't assume all adults are EBV-seropositive—3% remain seronegative with ongoing seroconversion risk 6
• Don't restrict screening only to young males—complications occur in females and older patients 1
• Don't delay necessary immunosuppression if EBV screening results are pending—the risk of undertreated IBD may outweigh EBV risks in many cases
• Don't confuse EBV screening recommendations for thiopurines with those for biologics—the evidence and risk profiles differ substantially
• Don't rely on EBV serology alone—it should be part of comprehensive viral screening including hepatitis B, C, HIV, and VZV 1

Monitoring After Treatment Initiation

The 2021 ECCO guidelines note that EBV was detected in 75% of IBD patients on anti-TNF and other immunosuppressants, with increased lymphoma risk 10. However, routine EBV monitoring during treatment is not standard practice. Clinical vigilance for symptoms of primary EBV infection or lymphoproliferative disorders is more important than serial EBV testing 1.

Nuances in the Evidence

The controversy around routine adult EBV screening reflects the tension between:

• Low absolute risk of complications in seropositive adults
• High seroprevalence making screening less cost-effective in adults
• Documented cases of severe complications across all age groups
• Availability of alternative immunosuppressive agents

The most recent high-quality evidence (2019 BSG guidelines) stops short of mandating universal screening in adults but strongly supports it in pediatric populations 1. The 2021 ECCO guidelines similarly recommend baseline EBV screening as part of comprehensive infectious workup 10.